Aligos Therapeutics to present new pevifoscorvir sodium clinical data at AASLD Liver Meeting 2026
ALGS•Aligos Therapeutics said five abstracts were accepted for AASLD’s The Liver Meeting 2026 in Denver, Nov. 5-9, with poster presentations scheduled for Nov. 7-8. The abstracts cover chronic hepatitis B, including immune effects and signs of sustained viral suppression, plus preclinical hepatitis B and hepatitis delta virus programs.
1. Conference presentations
Aligos Therapeutics said five abstracts were accepted for AASLD’s The Liver Meeting 2026 in Denver on Nov. 5-9, with posters scheduled for Nov. 7-8. The data include pevifoscorvir sodium in chronic hepatitis B, with reported immune effects and signs of sustained viral suppression over longer treatment; separate updates cover ALG-170675 for hepatitis B and preclinical ALG-215007, which showed antiviral activity against hepatitis delta virus in laboratory studies.
